Why eligibility decides more than personal preference

Most patients who arrive at this question have already spoken to a specialist — and the honest answer is that, for the majority, the choice is not really theirs to make. Eligibility criteria, not personal preference, determine which of these two treatments is a realistic option.

NHS funding for MACI is governed by NICE Technology Appraisal TA477 (2017), which sets four conditions that must all be met simultaneously. The defect must be focal and larger than 2 cm². The patient must not have had any prior cartilage surgery on the same knee. There must be minimal or no osteoarthritis in the joint. And the referral must be to a qualifying NHS tertiary centre. Failing any single criterion — even one — removes NHS-funded MACI as an available path, regardless of how well the patient scores on the others.

ChondroFiller injection operates with a considerably broader inclusion envelope. There is no minimum defect size, no upper age ceiling, and it remains an option for patients with Kellgren-Lawrence Grade III or IV osteoarthritis — the severity that definitively rules out MACI. Patients who have already undergone cartilage procedures on the same joint are not excluded either; those are precisely the populations MACI typically cannot serve.

One limit is shared by both: end-stage bone-on-bone arthritis, where cartilage regeneration of any kind falls outside what is therapeutically realistic. Short of that point, the two treatments address largely non-overlapping groups — which means that for many patients, the first practical question is not 'which is better?' but 'which applies to me?'

What each treatment pathway looks like

MACI involves two separate hospital episodes separated by weeks of waiting. At the first appointment, a surgeon takes an arthroscopic biopsy of healthy cartilage from the same joint — a keyhole procedure under anaesthesia. Those cells are sent to a specialist laboratory, where they are cultured and seeded onto a collagen membrane; this stage typically takes four to six weeks. The second appointment is the main operation: implantation via open or mini-arthrotomy under general or regional anaesthesia, with the prepared membrane fixed into the defect site. Structured rehabilitation then follows for 12 to 18 months before full return to activity.

ChondroFiller injection follows a fundamentally different timetable. The entire treatment takes place in a single 30–45 minute outpatient appointment. Under local anaesthesia only, an ultrasound-guided needle delivers the collagen gel directly into the defect, where it solidifies in situ within three to five minutes — no incision, no operating theatre, no general anaesthesia required. Patients walk out the same day. Mild soreness is common over the following 24–48 hours, and high-impact loading is restricted for one to two weeks before normal activity resumes.

There is also a structural difference in joint coverage. Under NICE criteria, MACI is approved for the knee only. ChondroFiller injection can be delivered across multiple joints — knee, hip, ankle, shoulder, elbow, wrist, and small hand joints — making it the only option discussed here for patients whose defect sits outside the knee.

For patients who cannot commit to two surgical episodes, prolonged rehabilitation, or extended time away from work or daily responsibilities, this procedural difference is clinically meaningful, not merely a question of personal preference.

How each treatment builds new cartilage

Beneath the procedural differences lies a more fundamental distinction: the two treatments recruit — or deliver — cells by entirely different means.

ChondroFiller injection is acellular, meaning it contains no cells at all. Once the injectable collagen gel solidifies in the defect, it acts as a scaffold — a structured framework that signals to the body's own repair cells to migrate inward. Those progenitor cells travel from the surrounding synovium (the joint's inner lining) and from the subchondral bone beneath the defect, gradually populating the matrix and, over 6–24 months, depositing new cartilage-like tissue in a process called matrix-induced chondrogenesis. A 2025 ex vivo study using 61 osteochondral explants provided direct laboratory evidence of this: ChondroFiller-treated samples showed a 2.4-fold increase in DNA content by day 14, confirming active cell recruitment into the scaffold within two weeks of application.

MACI works the other way around. Rather than inviting cells in, it pre-loads the repair site with them. Chondrocytes harvested from the patient's own cartilage are expanded in a laboratory, seeded onto a collagen membrane, and then surgically fixed into the prepared defect — delivering an active cell cargo directly to the site.

Both strategies aim at the same biological destination: restored cartilage tissue within a focal defect. One relies on the body's migratory response once a scaffold is in place; the other brings the cellular workforce to the site ready-made. Neither is viable where surrounding tissue and subchondral bone are too compromised to support regeneration — the shared biological floor that end-stage arthritis falls through.

What the clinical evidence shows for each

The two treatments have been studied separately, in different populations, and mostly in different joints — so the evidence bases run in parallel rather than converging on a direct comparison.

ChondroFiller injection

Published data span three joint sites. In the knee, a randomised multicentre study found significant IKDC improvements at 3, 6, and 12 months (p<0.05), with MRI confirming progressive cartilage maturation at 52 weeks and no adverse events reported. A separate knee cohort recorded significant gains in both Lysholm and IKDC scores. In the hip, a 26-patient cohort followed for three to five years found 17 of 21 evaluable patients achieving good or excellent results — though those with pre-existing Tönnis Grade 2–3 osteoarthritis fared poorly, reflecting the OA boundary both treatments share. A 2025 wrist study (25 ChondroFiller-treated patients versus 7 controls) showed significantly better cartilage quality at follow-up arthroscopy: median Outerbridge score 1.5 versus 3 (p=0.006) and ICRS score 1 versus 3 (p=0.002). An in vitro biomechanical study found ChondroFiller did not protect opposing cartilage under early cyclic loading, providing the mechanical rationale for the post-injection load restriction described in the previous section.

The consistent limitation across these studies is scale and duration: most involve fewer than 30 patients, with follow-up of 12 months or less. Whether scaffold-generated repair tissue maintains its mechanical properties over five to ten years remains unestablished.

MACI

MACI's evidence base is more volumetrically mature. A 2025 matched-pair study (n=48) found MACI equivalent to AMIC and minced cartilage at two years across VAS, KOOS-Pain, KOOS-Symptoms, KOOS-ADL, and KOOS-QOL, with all three groups improving significantly from baseline; the study describes MACI as the field's 'gold standard'. MACI has also been studied in ankle defects — an application outside the knee focus of NICE TA477: a 2025 systematic review of 166 patients treated for talar osteochondral lesions reported mean AOFAS functional scores (a 100-point ankle-outcome scale) rising from a pre-operative range of 36.9–70.1 to 78.3–95.3 post-operatively, with return-to-sport rates of 50–82.4%. Complication rates ranged from 0 to 59% and revision rates from 0 to 45%, indicating wide variability across studies.

No direct head-to-head trial of ChondroFiller injection versus MACI in matched knee populations exists. That is a genuine evidence gap, not a minor caveat: any comparison between the two depends on reading across separate studies conducted in different patient groups at different follow-up intervals.

Cost, access, and which joints are covered

For patients who meet all four NICE criteria, MACI carries no personal cost — NHS tertiary funding covers both stages. Those who do not qualify face private MACI, which is available at a small number of UK centres but at substantial expense.

ChondroFiller injection is delivered privately at the London Cartilage Clinic on Harley Street. Costs vary by joint and defect complexity but typically fall in the approximate range of £2,000–£6,000 — considerably less than a two-stage surgical pathway undertaken privately. These figures should be confirmed at assessment, as individual circumstances differ.

The anatomical asymmetry noted in earlier sections has a direct access implication: patients with defects outside the knee have no MACI route to consider under NICE, making ChondroFiller injection the relevant restorative option at those sites by default.

Access logistics differ too. MACI requires tertiary-centre referral as a NICE condition; ChondroFiller injection is accessible through a specialist outpatient assessment without that step. For patients facing a lengthy NHS wait, or with an early-stage defect at a non-knee site, that difference in access speed may be practically decisive.

A specialist assessment is the right starting point — it establishes which pathway is anatomically and clinically applicable before cost or logistics become relevant.

Getting an assessment at the London Cartilage Clinic

The comparison above resolves into a practical question: which pathway applies to you? Patients who meet all four NICE criteria for MACI — focal knee defect above 2 cm², no prior cartilage procedure on that knee, minimal osteoarthritis, and NHS tertiary-centre access — should discuss MACI through that referral route. Everyone else: those with defects outside the knee, those who have had prior cartilage work on the same joint, those with Kellgren-Lawrence Grade III or IV changes, and those who want to avoid a two-stage surgical pathway altogether, are appropriate candidates for a ChondroFiller injection assessment.

Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street. An assessment with Professor Paul Y. F. Lee — who leads the UK delivery of the treatment — will establish defect size, joint grade, and whether ChondroFiller injection or onward surgical referral is the right route. Technique and placement accuracy are clinically meaningful with this product, and that assessment is where individual suitability is determined.

Book at londoncartilage.com.

1. [1] MACI vs AMIC vs Arthroscopic Minced Cartilage — 2-year follow-up on pain and functional outcomes. (2025). https://doi.org/10.3390/jcm14072194 https://doi.org/10.3390/jcm14072194
2. [2] Favorable Short-Term Outcomes of MACI for Osteochondral Lesions of the Talus: Systematic Review. (2025). https://doi.org/10.1016/j.arthro.2025.07.045 https://doi.org/10.1016/j.arthro.2025.07.045
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: cohort study 12–60 months. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] Influence of cartilage defects and a collagen gel on corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
6. [6] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
7. [7] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration Investigation. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759